Department of Neurology and Neurosurgery, Dick White Referrals, Six Mile Bottom, Cambs, UK.
Department of Neurology and Neurosurgery, Dick White Referrals, Six Mile Bottom, Cambs, UK.
Top Companion Anim Med. 2021 Aug;44:100538. doi: 10.1016/j.tcam.2021.100538. Epub 2021 Apr 29.
Dexamethasone is the glucocorticoid of choice in many human inflammatory and immune-mediated conditions, given its reported effectiveness and limited side effect profile. In veterinary medicine, the glucocorticoid of choice is prednisone, however the safety of longer-term use of dexamethasone has not previously been studied. The aim of this study was to evaluate the safety, effectiveness and side effects of dexamethasone use as the glucocorticoid treatment for masticatory muscle myositis in dogs - an immune-mediated inflammatory condition. 93% of dogs showed a clinical improvement within two weeks of treatment, and 100% by ten weeks. 35% of dogs showed adverse reactions, however these were all mild and resolved with tapering of the dexamethasone dose. In conclusion, dexamethasone can be safely and effectively used for the treatment of masticatory muscle myositis in dogs, and should be considered for use in these cases, either alone or alongside additional immunosuppressive medications. Side effects are mild and resolve with tapering of the dexamethasone dose.
地塞米松是许多人类炎症和免疫介导性疾病的首选糖皮质激素,因为它具有良好的疗效和有限的副作用。在兽医领域,首选的糖皮质激素是泼尼松,但长期使用地塞米松的安全性尚未得到研究。本研究旨在评估地塞米松作为治疗犬咀嚼肌肌炎的糖皮质激素的安全性、有效性和副作用-一种免疫介导的炎症性疾病。93%的犬在治疗两周内显示出临床改善,100%在十周内显示出临床改善。35%的犬出现不良反应,但均为轻度,且随着地塞米松剂量的减少而缓解。总之,地塞米松可安全有效地用于治疗犬咀嚼肌肌炎,在这些情况下应考虑单独使用或联合其他免疫抑制药物使用。副作用轻微,随着地塞米松剂量的减少而缓解。